<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS157827</article-id><article-id pub-id-type="doi">10.1101/2022.11.24.517008</article-id><article-id pub-id-type="archive">PPR576332</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>Extracellular disintegration of viral proteins as an innovative strategy for developing broad-spectrum antivirals against coronavirus</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ding</surname><given-names>Zhe</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jia</surname><given-names>Xiaoying</given-names></name><xref ref-type="aff" rid="A3">c</xref><xref ref-type="aff" rid="A4">d</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cheng</surname><given-names>Haonan</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yingwen</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zhuoyu</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xiaohua</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Pu</surname><given-names>Fangxu</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Entao</given-names></name><xref ref-type="aff" rid="A5">e</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Guiyou</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="A3">c</xref></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Yun</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name><surname>Wong</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="A2">b</xref></contrib><contrib contrib-type="author"><name><surname>Chiu</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="A5">e</xref><xref ref-type="aff" rid="A6">f</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Lan</surname><given-names>Jiaming</given-names></name><xref ref-type="aff" rid="A2">b</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Aiguo</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>a</label>Shanghai Key Laboratory of Advanced Polymeric Materials, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China</aff><aff id="A2"><label>b</label>The Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China</aff><aff id="A3"><label>c</label>State Key Laboratory of Virology, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China</aff><aff id="A4"><label>d</label>University of the Chinese Academy of Sciences, Beijing 100049, China</aff><aff id="A5"><label>e</label>Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230027, China</aff><aff id="A6"><label>f</label>Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China</aff><author-notes><corresp id="CR1"><label>*</label>Correspondence to: <email>hagmhsn@ecust.edu.cn</email> (A.H.), <email>jmlan@ips.ac.cn</email> (J.L.), <email>qiux@ustc.edu.cn</email> (S.C.)</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>28</day><month>11</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has claimed millions of lives worldwide, not to mention innumerable losses in the global economy and disruptions in social relationships. Unfortunately, state-of-the-art treatments still lag behind the fast emergence of new variants of concern. The key to resolve this issue is to develop broad-spectrum antivirals with innovative antiviral mechanisms in which coronaviruses are deactivated regardless of their variant development. Herein, we report a new antiviral strategy involving extracellular disintegration of viral proteins that are indispensable for viral infection with hyperanion-grafted enediyne molecules. The sulfate groups ensure low cellular permeability and rather low cytotoxicity of the molecules, while the core enediyne generates reactive radical species and causes significant damage to the spike (S) protein of coronavirus. The enediyne compounds exhibit antiviral activity at micromolar to nanomolar concentrations, and the selectivity index of up to 20,000 against four kinds of human coronaviruses, including the SARS-CoV-2 omicron variant, suggesting the high potential of this new strategy in combating the COVID-19 pandemic.</p></abstract><kwd-group><kwd>Enediynes</kwd><kwd>Antiviral agents</kwd><kwd>Broad-spectrum</kwd><kwd>Coronavirus</kwd><kwd>SARS-CoV-2</kwd></kwd-group></article-meta></front><body><p id="P2">The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused serious damage to human health, social relationships, and the global economy. Since its first identification in early 2020(<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>), the culprit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has accumulated thousands of mutations(<xref ref-type="bibr" rid="R3">3</xref>). The World Health Organization (WHO) has listed a series of variants of concern (VOCs) in the last two years, including the predominant alpha, delta and omicron variants that caused significant infection waves worldwide. The rapid mutation of SARS-CoV-2 and fast emergence of new VOCs constitute a great challenge to the colony immune defense by widespread vaccination and antiviral developments, as most of them are designed in the “one bug-one drug” approach. Developing broad-spectrum antivirals, <italic>ideally with an innovative antiviral mechanism</italic>, is therefore of essential importance to combat the current COVID-19 and future “disease X”(<xref ref-type="bibr" rid="R4">4</xref>) likely caused by other zoonotic viruses as the confronting of the previously distinct ecological niches becomes more frequent(<xref ref-type="bibr" rid="R5">5</xref>).</p><p id="P3">SARS-CoV-2 and six other known human coronaviruses are enveloped viruses. They are composed of lipid bilayers and four structural proteins, namely, spike (S), membrane (M), envelope (E) and nucleocapsid (N) proteins, with which the viral genome (approximately 30 kb) is safely wrapped. The S proteins are responsible for the interaction with the receptors on the cell surface to penetrate the host cells and further hijack the cellular reproduction machinery(<xref ref-type="bibr" rid="R6">6</xref>). Significant efforts have been devoted to developing antivirals against SARS-CoV-2 by blocking the cell entry process using engineered small molecules, proteins, adaptors, and extracellular vesicles to interrupt the binding of S protein to angiotensin converting enzyme 2 (ACE 2) cell receptor(<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R7">7</xref>-<xref ref-type="bibr" rid="R12">12</xref>). As the glycocalyx on the cell surface is negatively charged(<xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref>), the electrostatic interaction between glycans and the positively charged receptor binding domains (RBD) and additional binding sites in the S proteins provides localization of the virus for their cellular binding(<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R16">16</xref>). To this end, synthetic glycan analogs have been developed as broad-spectrum antivirals. For example, a variety of materials with multiple sulfate (or sulfonate) groups showed prominent results in treating with SARS-CoV-2(<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref>). Unfortunately, polyanionic systems are anticoagulant in nature, which may increase the risk of off-target adverse effects. Meanwhile, their inhibitory effect toward virus particles might be lost upon dilution in body fluid, resulting in revival of virus infection.</p><p id="P4">Enediynes, a family of compounds with a (Z)-hexa-3-en-1,5-diyne core structure, first discovered in the 1960s from the culture filtrates of <italic>Streptomyces</italic>(<xref ref-type="bibr" rid="R20">20</xref>), exert profound biological activity through a hitherto unseen mode of action. After a special triggering mechanism, the activated enediynes undergo Bergman cyclization or Myers-Saito cyclization to generate highly reactive radical species, which further abstract H-atoms from DNA or proteins and show catastrophic effects on tumor cell proliferation(<xref ref-type="bibr" rid="R21">21</xref>). While natural enediynes are rather scarce and difficult to synthesize(<xref ref-type="bibr" rid="R22">22</xref>), we recently uncovered a new mechanism, namely, maleimide-assisted rearrangement and cycloaromatization (MARACA, <xref ref-type="fig" rid="F1">Fig. 1A</xref>), enabling the structurally much simpler synthetic enediyne to generate radical species in a physiological environment and exhibit remarkable antitumor activity(<xref ref-type="bibr" rid="R23">23</xref>). Herein, we report a new strategy for developing broad-spectrum antivirals by installing multiple anionic groups (sulfate groups in this work) onto enediynes. The anionic groups are beneficial for directing the enediyne “warhead” to the S protein of coronavirus through electrostatic interactions. Meanwhile, polyanionic compounds are cell impermeable(<xref ref-type="bibr" rid="R24">24</xref>), which ensures rather low cytotoxicity to normally functioning cells and the extracellular disintegration of the viral proteins by the radical species generated through MARACA.</p><p id="P5"><xref ref-type="fig" rid="F1">Figure 1B</xref> shows the chemical structures of the sulfated enediynes (<bold>EDY-A</bold> ~ <bold>EDY-E</bold>), and the detailed synthetic procedures and structural characterizations for these compounds can be found in the <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref>. Starting from commercially available reagents, these enediynes were synthesized in the longest linear sequence (LLS) of no more than five steps, suggesting their ready scaling-up for future mass production. The first two steps for the preparation of 3,4-diiodomaleimide (<bold>2</bold>) were well documented in our previous work(<xref ref-type="bibr" rid="R25">25</xref>). The core enediyne structures were constructed in the third step through a Sonogashira coupling reaction between <bold>2</bold> and terminal alkynes, which are either commercially available or synthesized in less than three steps. The enediynes with 1, 2, 4, and 6 hydroxy groups were then hypersulfated in N,N-dimethylformamide (DMF) with excess SO<sub>3</sub>-DMF and neutralized with cold sodium bicarbonate solution followed by removal of inorganic salts and lyophilization to give <bold>EDY-A</bold> ~ <bold>EDY-E</bold> in high yields. For the synthesis of <bold>EDY-D</bold> and <bold>EDY-E</bold>, an extra step was needed to remove the ketal protection groups before hypersulfation.</p><p id="P6">The radical-generating property of the enediynes was characterized with electron paramagnetic resonance (EPR) spectroscopy by exploiting a radical trapping strategy. Taking <bold>EDY-A</bold> and <bold>EDY-B</bold> as examples, the appearance of triplet doublet signals in the EPR spectra (<xref ref-type="fig" rid="F2">Fig. 2A</xref>) suggests the generation of radical species from enediynes followed by trapping with N-tert-butyl-α-phenylnitrone (PBN)(<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R26">26</xref>). It is noteworthy that under the same conditions, the peaks shown in the EPR spectrum of <bold>EDY-A</bold> are more profound than those for <bold>EDY-B</bold>. We recently confirmed that the introduction of an oxygen atom at the propargyl position of one alkynyl arm of enediyne compounds (such as the one in <bold>EDY-A</bold>) leads to a much faster reaction due to the facilitation of a cascade rearrangement and cycloaromatization with an approximately 6 kcal/mol lower energy barrier(<xref ref-type="bibr" rid="R27">27</xref>).</p><p id="P7">The highly reactive radicals generated from enediynes abstract hydrogen atoms from the protein backbone and lead to oxidative disintegration of protein structure and functionality(<xref ref-type="bibr" rid="R28">28</xref>). To test the ability of enediynes to destroy viral structural proteins, the S protein of SARS-CoV-2 was incubated at 37°C with gradient concentrations of enediynes. Western blot analysis results (<xref ref-type="fig" rid="F2">Fig. 2B</xref>) indicate that the disintegration of S protein is concentration and time dependent. At a concentration of 0.25 mM, <bold>EDY-A</bold> led to significant degradation of the S protein within 2 h of incubation, and further degradation of the S protein was observed at longer incubation time. In comparison, <bold>EDY-B</bold> shows a lower protein disintegration ability at the same time interval, which is in line with its slower radical generation rate, as mentioned above. The protein disintegration results of <bold>EDY-C</bold>~<bold>EDY-E</bold> exhibited a similar trend and are shown in the <xref ref-type="supplementary-material" rid="SD1">supplementary material (Fig. S1)</xref>. To further confirm the radical nature of the disintegration of viral protein by enediyne, S protein was coincubated with <bold>EDY-D</bold> (5 mM) and serial dilutions of a radical scavenger vitamin C(<xref ref-type="bibr" rid="R29">29</xref>). At a high concentration of the radical scavenger, the S protein remained intact after incubation at 37°C for 12 h. When the concentration of the radical scavenger was comparable to or lower than that of <bold>EDY-D</bold>, the breakdown or even complete disintegration of the S protein was clearly observed (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>). The structural integrity of the S protein is essential for viral infection(<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R31">31</xref>). Therefore, disintegrating the S protein of coronavirus with enediyne compounds provides a straightforward way to diminish infectivity and eventually deactivate viral particles.</p><p id="P8">The extremely high cytotoxicity has been the hallmark of enediyne antitumor antibiotics since their early discovery and development. Indeed, two kinds of antibody drug conjugates have been approved for the clinical treatment of leukemia with enediynes as the “warheads”(<xref ref-type="bibr" rid="R32">32</xref>). The cytotoxicity of enediynes originates from the intercalation of enediyne into the minor groove of DNA, followed by the generation of radical species, abstraction of hydrogen atoms from DNA, and dysfunction of DNA, which leads to cellular apoptosis. On the other hand, to utilize enediynes as the “warheads” for viral protein disintegration, the cellular entrance process of enediynes must be suppressed to make them benign to normally functioning cells. To this end, the cellular uptake of enediynes with or without sulfate group(s) was studied by confocal laser scanning microscopy (CLSM). As shown in <xref ref-type="fig" rid="F3">Fig. 3</xref>, after grafting with one sulfate group, the internalization of enediyne by HeLa cells was significantly inhibited. For <bold>EDY-B</bold> with two sulfate groups, no cellular uptake was observed. For <bold>EDY-C</bold>~<bold>EDY-E</bold> with more sulfate groups, no cellular internalization of the enediynes was found (<xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>), suggesting no harmful effect of these enediynes to cells.</p><p id="P9">With all the information for the extracellular dysfunction of coronavirus in hand, the sulfated enediynes were then evaluated for their ability against human seasonal coronavirus (hCoV-229E, hCoV-NL63 and hCoV-OC43) infections by plaque reduction assay (<xref ref-type="supplementary-material" rid="SD1">supplementary materials</xref>) in sensitive cell lines (Huh-7, hACE2/Caco2 and RD, respectively). All of the sulfated enediynes showed obvious inhibitory effects with a median effective concentration (EC<sub>50</sub>) value of 3.86 μM~137.2 μM (<xref ref-type="fig" rid="F4">Fig. 4</xref>). Interestingly, enediynes with oxygen atoms at the propargyl position (<bold>EDY-A</bold>, <bold>EDY-D</bold> and <bold>EDY-E</bold>) showed high antiviral activities of inhibiting seasonal coronavirus growth with an EC50 of approximately 10 μM, while the enediynes (<bold>EDY-B</bold> and <bold>EDY-C</bold>) without this kind of activating functionality(<xref ref-type="bibr" rid="R27">27</xref>) exhibited an order of magnitude lower antiviral activity, correlating with their relatively slower radical generating rate and weaker viral protein disintegration ability, as discussed above.</p><p id="P10">The cytotoxicity of enediynes was tested based on a CCK-8 cell counting kit. The Huh-7, hACE2/Caco-2 and RD cells were seeded separately into 96-well microplates (10<sup>4</sup> cells per well at 100 μL) and cocultured with enediynes at 37 °C (<xref ref-type="supplementary-material" rid="SD1">supplementary materials</xref>). The good consistency of low cytotoxicity in different cell lines was shown as half cytotoxic concentration (CC<sub>50</sub>) values of approximately 1 mM in <bold>EDY-A</bold>, <bold>EDY-B</bold> and <bold>EDY-D</bold> (<xref ref-type="fig" rid="F4">Fig. 4</xref>). In addition, <bold>EDY-C</bold> did not exhibit any cytotoxicity even at the highest working concentration (1 mM), which probably benefited from the grafting of six sulfate groups that completely shut down drug entry into the cell to interact with host proteins (and/or DNA). Surprisingly, <bold>EDY-E</bold> showed an order of magnitude higher cytotoxicity even though it is structurally almost the same as <bold>EDY-D</bold>. We speculate that the relatively labile ester linkage in <bold>EDY-E</bold> would lead to the serendipitous release of trace amounts of enediyne core and cause harm to cells due to the high cytotoxicity of the uncharged enediyne(<xref ref-type="bibr" rid="R23">23</xref>). Altogether, we conclude that the enediyne core is responsible for viral deactivation, while the sulfate groups are indispensable for low cytotoxicity. Both of these parts and the strong linkage between them are essential for antiviral molecular design. For example, <bold>EDY-D</bold> typically showed a high selectivity index (SI, defined as CC<sub>50</sub>/ EC<sub>50</sub>), suggesting a wide application window for potential antiviral treatment.</p><p id="P11">Unlike human seasonal coronavirus, which typically infects the upper respiratory tract and causes mild symptoms, SARS-CoV-2 can replicate in the lower respiratory tract and is more dangerous, causing much higher morbidity and mortality. The emergence of the VOC omicron and its subvariants with extremely high transmissibility and immune evasion constitute a great challenge to all the current countermeasures(<xref ref-type="bibr" rid="R33">33</xref>–<xref ref-type="bibr" rid="R35">35</xref>). To this end, we tested the performance of <bold>EDY-A</bold>~<bold>EDY-E</bold> for SARS-CoV-2 omicron treatment. The cytotoxicity experiments of these enediynes to Vero E6 cells were performed regularly, while the antiviral experiments involving SARS-CoV-2 omicron were executed in a biosafety level 3 (BSL-3) laboratory. Encouragingly, all the enediynes showed highly promising antiviral results (<xref ref-type="fig" rid="F4">Fig. 4</xref>). The enediynes with a higher tendency to undergo MARACA and generate radical species typically showed higher antiviral activity. The enediyne with the best performance is <bold>EDY-D</bold>, exhibiting an EC<sub>50</sub> of 56.19 nM (~50 ng/mL) and an SI value of over 20,000. The higher antiviral activity of these enediynes toward SARS-CoV-2 omicron than that for the human seasonal viruses is probably due to the enhanced electrostatic interaction between these (poly)sulfated enediynes with the omicron S protein. The omicron S protein shows a positively charged electrostatic surface mainly acquired through N440K, T478K, Q493R, Q498R and Y505H mutations(<xref ref-type="bibr" rid="R34">34</xref>). While the mutation of the S protein indeed promotes ACE2 recognition, facilitates the infection and transmission of SARS-CoV-2 omicron and is probably responsible for immune evasion of the majority of neutralizing antibodies, when met with these polysulfated enediynes, it goes to the dead end.</p><p id="P12">In conclusion, we developed an innovative antiviral strategy by employing hyperanion-grafted enediynes to deactivate coronavirus. The core enediyne generates reactive free radical species and causes significant damage to viral proteins and abolishes their function, which is similar to many free radical-generating sanitizing agents. Meanwhile, the anionic groups endow the molecules with rather low cellular permeability and low cytotoxicity and probably guide the enediyne moieties to the RBD region of the S protein, where the peptide chain is positively charged. Overall, this extracellular ultrasanitizing treatment allows disinfection of a broad spectrum of human coronaviruses, including SARS-CoV-2 omicron variants, down to nanomolar concentrations with a high selectivity index for safe use. As the disintegration of viral protein by enediyne is insensitive to the epitopes or subtle structural change of viral proteins, this strategy would also inspire the development of antivirals against other kinds of viruses to fill the huge demand-supply gap(<xref ref-type="bibr" rid="R36">36</xref>) and might serve as strategic stockpile for combating future “disease X”.</p><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>supplemental materials</label><media xlink:href="EMS157827-supplement-supplemental_materials.docx" mimetype="application" mime-subtype="vnd.openxmlformats-officedocument.wordprocessingml.document" id="d83aAdLbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S1"><title>Acknowledgments</title><p>We thank Drs. Junyou Wang and Runhui Liu for the helpful discussions and assistance in the synthesis and biological tests.</p><sec id="S2"><title>Funding</title><p>Supported by National Natural Science Foundation of China (21871080) and “Eastern Scholar Professorship” (for A.H.) and the Natural Science Foundation of Shanghai (20ZR1463900) (for J.L.).</p></sec></ack><sec id="S3" sec-type="data-availability"><title>Data and materials availability</title><p id="P13">All data are available in the manuscript or the <xref ref-type="supplementary-material" rid="SD1">supplementary materials</xref>.</p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P14"><bold>Author contributions:</bold> Conceptualization: A.H. and J.L. Synthesis and Characterization: K.S., H.C., Z.L., X.H., and F.P. Cellular Tests: Z.D. and K.S. Antiviral Experiments: Z.D., X.J., Y.W., and E.L. Supervision: A.H., J.L., S.C., and W.W. Funding acquisition: A.H., J.L., S.C., and G.W. Writing-original draft: A.H., J.L., and K.S. Writing-review and editing: Y.D., J.L., A.H., S.C. and G.W.</p></fn><fn id="FN2" fn-type="conflict"><p id="P15"><bold>Competing interests:</bold> The Institut Pasteur of Shanghai (Chinese Academy of Sciences), East China University of Science and Technology and University of Science and Technology of China have coapplied for patents that cover EDY-A ~ EDY-E and related hyperanion-grafted enediyne compounds as broad-spectrum antivirals against coronavirus.</p></fn></fn-group><ref-list><title>References and notes</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><year>2020</year><volume>579</volume><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmcid">PMC7095418</pub-id><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><etal/></person-group><article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmcid">PMC7092803</pub-id><pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>W</given-names></name><etal/></person-group><article-title>Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>1048</fpage><lpage>1053</lpage><pub-id pub-id-type="pmcid">PMC8939775</pub-id><pub-id pub-id-type="pmid">35133176</pub-id><pub-id pub-id-type="doi">10.1126/science.abn8863</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Kerkhove</surname><given-names>MD</given-names></name><name><surname>Ryan</surname><given-names>MJ</given-names></name><name><surname>Ghebreyesus</surname><given-names>TA</given-names></name></person-group><article-title>Preparing for “Disease X”</article-title><source>Science</source><year>2021</year><volume>374</volume><fpage>377</fpage><pub-id pub-id-type="pmid">34643114</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigant</surname><given-names>F</given-names></name><name><surname>Santos</surname><given-names>NC</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name></person-group><article-title>Broad-spectrum antivirals against viral fusion</article-title><source>Nat Rev Microbiol</source><year>2015</year><volume>13</volume><fpage>426</fpage><lpage>437</lpage><pub-id pub-id-type="pmcid">PMC4554337</pub-id><pub-id pub-id-type="pmid">26075364</pub-id><pub-id pub-id-type="doi">10.1038/nrmicro3475</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name></person-group><article-title>How SARS-CoV-2 first adapted in humans</article-title><source>Science</source><year>2021</year><volume>372</volume><fpage>466</fpage><lpage>467</lpage><pub-id pub-id-type="pmid">33926942</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>Y-J</given-names></name><etal/></person-group><article-title>Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="pmcid">PMC9400459</pub-id><pub-id pub-id-type="pmid">34990214</pub-id><pub-id pub-id-type="doi">10.1126/science.abm8143</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Covalently Engineered Protein Minibinders with Enhanced Neutralization Efficacy against Escaping SARS-CoV-2 Variants</article-title><source>J Am Chem Soc</source><year>2022</year><volume>144</volume><fpage>5702</fpage><lpage>5707</lpage><pub-id pub-id-type="pmcid">PMC8905923</pub-id><pub-id pub-id-type="pmid">35212528</pub-id><pub-id pub-id-type="doi">10.1021/jacs.1c11554</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname><given-names>MN</given-names></name><name><surname>Hintzen</surname><given-names>JCJ</given-names></name><name><surname>Löffler</surname><given-names>PMG</given-names></name><name><surname>Mecinović</surname><given-names>J</given-names></name></person-group><article-title>Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides</article-title><source>Chem Commun</source><year>2021</year><volume>57</volume><fpage>3283</fpage><lpage>3286</lpage><pub-id pub-id-type="pmid">33651072</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>F</given-names></name><etal/></person-group><article-title>Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy</article-title><source>Adv Mater</source><year>2021</year><volume>33</volume><elocation-id>2103471</elocation-id><pub-id pub-id-type="pmcid">PMC8646473</pub-id><pub-id pub-id-type="pmid">34665481</pub-id><pub-id pub-id-type="doi">10.1002/adma.202103471</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection</article-title><source>Angew Chem, Int Ed</source><year>2021</year><volume>60</volume><fpage>10266</fpage><lpage>10272</lpage><pub-id pub-id-type="pmcid">PMC8014204</pub-id><pub-id pub-id-type="pmid">33561300</pub-id><pub-id pub-id-type="doi">10.1002/anie.202100225</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilboa</surname><given-names>T</given-names></name><etal/></person-group><article-title>A SARS-CoV-2 Neutralization Assay Using Single Molecule Arrays</article-title><source>Angew Chem, Int Ed</source><year>2021</year><volume>60</volume><fpage>25966</fpage><lpage>25972</lpage><pub-id pub-id-type="pmcid">PMC8653099</pub-id><pub-id pub-id-type="pmid">34534408</pub-id><pub-id pub-id-type="doi">10.1002/anie.202110702</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koehler</surname><given-names>M</given-names></name><name><surname>Delguste</surname><given-names>M</given-names></name><name><surname>Sieben</surname><given-names>C</given-names></name><name><surname>Gillet</surname><given-names>L</given-names></name><name><surname>Alsteens</surname><given-names>D</given-names></name></person-group><article-title>Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans</article-title><source>Annu Rev Virol</source><year>2020</year><volume>7</volume><fpage>143</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">32396772</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagno</surname><given-names>V</given-names></name><name><surname>Tseligka</surname><given-names>ED</given-names></name><name><surname>Jones</surname><given-names>ST</given-names></name><name><surname>Tapparel</surname><given-names>C</given-names></name></person-group><article-title>Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias?</article-title><source>Viruses</source><year>2019</year><volume>11</volume><fpage>596</fpage><pub-id pub-id-type="pmcid">PMC6669472</pub-id><pub-id pub-id-type="pmid">31266258</pub-id><pub-id pub-id-type="doi">10.3390/v11070596</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2</article-title><source>ACS Cent Sci</source><year>2021</year><volume>7</volume><fpage>1009</fpage><lpage>1018</lpage><pub-id pub-id-type="pmcid">PMC8227597</pub-id><pub-id pub-id-type="pmid">34235261</pub-id><pub-id pub-id-type="doi">10.1021/acscentsci.1c00010</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausen</surname><given-names>TM</given-names></name><etal/></person-group><article-title>SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1043</fpage><lpage>1057</lpage><pub-id pub-id-type="pmcid">PMC7489987</pub-id><pub-id pub-id-type="pmid">32970989</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2020.09.033</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabeen</surname><given-names>M</given-names></name><name><surname>Dutot</surname><given-names>M</given-names></name><name><surname>Fagon</surname><given-names>R</given-names></name><name><surname>Verrier</surname><given-names>B</given-names></name><name><surname>Monge</surname><given-names>C</given-names></name></person-group><article-title>Seaweed Sulfated Polysaccharides against Respiratory Viral Infections</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><fpage>733</fpage><pub-id pub-id-type="pmcid">PMC8156470</pub-id><pub-id pub-id-type="pmid">34065660</pub-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13050733</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>C</given-names></name><etal/></person-group><article-title>Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions**</article-title><source>Angew Chem, Int Ed</source><year>2021</year><volume>60</volume><fpage>15870</fpage><lpage>15878</lpage><pub-id pub-id-type="pmcid">PMC8250366</pub-id><pub-id pub-id-type="pmid">33860605</pub-id><pub-id pub-id-type="doi">10.1002/anie.202102717</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Modified cyclodextrins as broad-spectrum antivirals</article-title><source>Sci Adv</source><year>2020</year><volume>6</volume><elocation-id>eaax9318</elocation-id><pub-id pub-id-type="pmcid">PMC6989148</pub-id><pub-id pub-id-type="pmid">32064341</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.aax9318</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>N</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Kumagai</surname><given-names>K</given-names></name><name><surname>Rikimaru</surname><given-names>M</given-names></name></person-group><article-title>Neocarzinostatin, antitumor antibiotic of high molecular weight; isolation, physicochemical properties, and biological activities</article-title><source>J Antibiot, Ser A</source><year>1965</year><volume>18</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">14326086</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kar</surname><given-names>M</given-names></name><name><surname>Basak</surname><given-names>A</given-names></name></person-group><article-title>Design, Synthesis, and Biological Activity of Unnatural Enediynes and Related Analogues Equipped with pH-Dependent or Phototriggering Devices</article-title><source>Chem Rev</source><year>2007</year><volume>107</volume><fpage>2861</fpage><lpage>2890</lpage><pub-id pub-id-type="pmid">17590056</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolaou</surname><given-names>KC</given-names></name><name><surname>Rigol</surname><given-names>S</given-names></name></person-group><article-title>Total Synthesis in Search of Potent Antibody-Drug Conjugate Payloads From the Fundamentals to the Translational</article-title><source>Acc Chem Res</source><year>2019</year><volume>52</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">30575399</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Triggering the Antitumor Activity of Acyclic Enediyne through Maleimide-Assisted Rearrangement and Cycloaromatization</article-title><source>J Org Chem</source><year>2020</year><volume>85</volume><fpage>9808</fpage><lpage>9819</lpage><pub-id pub-id-type="pmid">32657121</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kand</surname><given-names>D</given-names></name><etal/></person-group><article-title>Water-Soluble BODIPY Photocages with Tunable Cellular Localization</article-title><source>J Am Chem Soc</source><year>2020</year><volume>142</volume><fpage>4970</fpage><lpage>4974</lpage><pub-id pub-id-type="pmcid">PMC7302507</pub-id><pub-id pub-id-type="pmid">32115942</pub-id><pub-id pub-id-type="doi">10.1021/jacs.9b13219</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group><article-title>Synthesis of maleimide-based enediynes with cyclopropane moieties for enhanced cytotoxicity under normoxic and hypoxic conditions</article-title><source>J Mater Chem B</source><year>2021</year><volume>9</volume><fpage>4502</fpage><lpage>4509</lpage><pub-id pub-id-type="pmid">34019610</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usuki</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>M</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name><name><surname>Ellestad</surname><given-names>GA</given-names></name></person-group><article-title>Calicheamicin gamma(I)(1) and phenyl tert-butyl nitrone (PBN): observation of a kinetic isotope effect by an ESR study</article-title><source>Chem Commun</source><year>2010</year><volume>46</volume><fpage>737</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">20087504</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Experimental and Computational Study on the Intramolecular Hydrogen Atom Transfer Reactions of Maleimide-Based Enediynes After Cycloaromatization</article-title><source>J Org Chem</source><year>2021</year><volume>86</volume><fpage>1549</fpage><lpage>1559</lpage><pub-id pub-id-type="pmid">33372795</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bdour</surname><given-names>HM</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Basak</surname><given-names>A</given-names></name></person-group><article-title>Proteins as Alternate Targets of Enediynes</article-title><source>Lett Drug Des Discovery</source><year>2015</year><volume>12</volume><fpage>545</fpage><lpage>557</lpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gebicki</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Reduction of protein radicals by GSH and ascorbate: potential biological significance</article-title><source>Amino Acids</source><year>2010</year><volume>39</volume><fpage>1131</fpage><lpage>1137</lpage><pub-id pub-id-type="pmid">20532951</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Distinct conformational states of SARS-CoV-2 spike protein</article-title><source>Science</source><year>2020</year><volume>369</volume><fpage>1586</fpage><lpage>1592</lpage><pub-id pub-id-type="pmcid">PMC7464562</pub-id><pub-id pub-id-type="pmid">32694201</pub-id><pub-id pub-id-type="doi">10.1126/science.abd4251</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toelzer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>725-+</fpage><pub-id pub-id-type="pmcid">PMC8050947</pub-id><pub-id pub-id-type="pmid">32958580</pub-id><pub-id pub-id-type="doi">10.1126/science.abd3255</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolaou</surname><given-names>KC</given-names></name><name><surname>Rigol</surname><given-names>S</given-names></name></person-group><article-title>The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies</article-title><source>Angew Chem, Int Ed</source><year>2019</year><volume>58</volume><fpage>11206</fpage><lpage>11241</lpage><pub-id pub-id-type="pmid">31012193</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies</article-title><source>Nature</source><year>2022</year><volume>602</volume><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="pmcid">PMC8866119</pub-id><pub-id pub-id-type="pmid">35016194</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-04385-3</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>H-H</given-names></name><name><surname>Zinno</surname><given-names>J</given-names></name><name><surname>Piano</surname><given-names>F</given-names></name><name><surname>Gunsalus</surname><given-names>K</given-names></name></person-group><article-title>Omicron Spike Protein Has a Positive Electrostatic Surface That Promotes ACE2 Recognition and Antibody Escape</article-title><source>Front Virol</source><year>2022</year><volume>2</volume></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5</article-title><source>Nature</source><year>2022</year><volume>608</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="pmcid">PMC9385487</pub-id><pub-id pub-id-type="pmid">35790190</pub-id><pub-id pub-id-type="doi">10.1038/s41586-022-05053-w</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamson</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Antiviral drug discovery: preparing for the next pandemic</article-title><source>Chem Soc Rev</source><year>2021</year><volume>50</volume><fpage>3647</fpage><lpage>3655</lpage><pub-id pub-id-type="pmid">33524090</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>A) Schematic illustration of the radical generation mechanism of maleimide-based enediyne compounds. B) Chemical structures of enediyne antivirals reported in this work.</p></caption><graphic xlink:href="EMS157827-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>A) EPR spectra of EDY-A and EDY-B after treatment with the spin trapping agent PBN. B) and C) Western blot analysis results of the SARS-CoV-2 S protein after incubation with EDY-A or EDY-B, respectively. The lines marked with “0 h” indicate the standard S protein samples.</p></caption><graphic xlink:href="EMS157827-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Comparison of the cellular entrance behavior of sulfated enediynes (<bold>EDY-A</bold> and <bold>EDY-B</bold>) with their counterparts (<bold>EDY-1</bold> and <bold>EDY-2</bold>) with confocal laser scanning microscopy. HeLa cells are stained with propidium iodide (PI), showing red fluorescence, while maleimide-based enediynes show intrinsic blue fluorescence(<xref ref-type="bibr" rid="R23">23</xref>).</p></caption><graphic xlink:href="EMS157827-f003"/></fig><fig id="F4" position="float"><label>Fig 4</label><caption><p>Antiviral activity of enediynes against four kinds of human coronaviruses by plaque reduction assays. Sensitive cell lines were selected for the corresponding coronavirus. The cytotoxicity of these enediynes to different cell lines was measured by CCK-8 assays. The left and right Y-axes of the graphs represent the mean cell variability and inhibition of viral infection in the presence of the enediynes, respectively. A table summarizing all the CC<sub>50</sub>, EC<sub>50</sub> and SI data can be found in the <xref ref-type="supplementary-material" rid="SD1">supplementary materials (Table S1)</xref></p></caption><graphic xlink:href="EMS157827-f004"/></fig></floats-group></article>